Daiichi Sankyo

Daiichi Sankyo Co., Ltd.

Type	Public KK (TYO: 4568)
Industry	Pharmaceutical
Founded	2005 (by merger)
Headquarters	Tokyo, Japan
Key people	Takashi Shoda, Chairman Joji Nakayama, President & CEO
Revenue	$11.655 billion USD (¥ 967.4 billion JPY) (FY 2010)
Net income	¥ 131,800 million JPY (FY 2010)
Employees	30,488 (2010) products = Pharmaceutical products
Website	www.daiichisankyo.com

Daiichi Sankyo Co., Ltd. (第一三共株式会社, Daiichi Sankyō Kabushiki-kaisha^?, TYO: 4568) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 970 billion in revenue in 2010 and is currently ranked number 17 in world sales. Its headquarter is based in Tokyo. The company also owns the American biotechnology company Plexxikon, the German biotechnology company U3 and Ranbaxy Laboratories in India. Daiichi Sankyo is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. with total sales of USD 2.7 billion.

Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in New Jersey.

Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.

Daiichi Sankyo Co., Ltd. is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

History

Daiichi Sankyo was established in 2005 through the merger of Sankyo Co., Ltd. (三共株式会社, Sankyō Kabushiki Kaisha^?) and Daiichi Pharmaceutical Co., Ltd. (第一製薬株式会社, Daiichi Seiyaku Kabushiki Kaisha^?), which were century-old pharmaceutical companies based in Japan.

Acquisitions

In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of Astellas Pharma.

On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion.^[1][2]

In June 2008, Daiichi Sankyo acquired U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio.^[3]

On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, a Berkley CA-based pharmaceutical start-up company for $805 and an additional $130 in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (GSK licensed) drug. ^[4]

Products of Daiichi Sankyo Group

Sankyo

• Benicar (olmesartan medoxomil)
• Mevalotin (pravastatin)
• Loxonin (loxoprofen)
• Hirudoid
• Olmetec (olmesartan)
• Captopril
• WelChol (colesevelam HCl)
• Effient (Prasugrel) (co-marketed with Eli Lilly and Company)
• win bp piramal (olmesartan medoxomil)
• Panipenem

Daiichi Pharmaceutical

• Cravit (levofloxacin)
• Evoxac (cevimeline)
• FloxinOtic (ofloxacin)
• Gracevit (sitafloxacin, only sold in Japan)

Pipeline candidates

Select mid-stage and late-stage investigational candidates in Daiichi-Sankyo's pipeline include:

• CS-011 (rivoglitazone)—Type 2 Diabetes
• CS-1008—Oncology
• CS-8958 (Laninamivir)—Influenza
• DU-176b—Venous thromboembolism
• SUN-11031—Cachexia

References

1. ^ Daiichi to get 35% stake in Ranbaxy
2. ^ The Brand Blog: Ranbaxy promoters to sell stake to Japan's Daiichi
3. ^ staff (2008-06-15). Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.): p. 8. 
4. ^ "Daiichi Sankyo To Acquire Plexxiko". http://www.plexxikon.com/view.cfm/88/Press-Releases. 

• Daiichi Sankyo Annual Report 2008

External links

• (Japanese) Daiichi Sankyo
• Jeffrey Bowman Vs. Daiichi Pharmaceuticals

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.v · Categories: Companies listed on the Tokyo Stock Exchange Pharmaceutical companies of Japan Companies based in Tokyo Japanese company stubs Medical company stubs Wikimedia Foundation. 2010. Игры ⚽ Нужен реферат? Fukushima Daiichi Nuclear Power Plant Daijee Look at other dictionaries: Daiichi Sankyō — K.K. (jap. 第一三共株式会社, Daichi Sankyō Kabushiki gaisha, engl. Daiichi Sankyo Co., Ltd.) ist eine gemeinsame japanische Holdinggesellschaft, die am 28. September 2005 durch die beiden japanischen Pharmafirmen Sankyō K.K. (三共株式会社, engl. Sankyo Co.,… …   Deutsch Wikipedia Daiichi Sankyo — Тип публичная кабусики гайся Листинг на бирже TYO: 4568, OSX …   Википедия Daiichi Sankyo — Daiichi Sankyō K.K. (jap. 第一三共株式会社, Daichi Sankyō Kabushiki gaisha, engl. Daiichi Sankyo Co., Ltd.) ist eine gemeinsame japanische Holdinggesellschaft, die am 28. September 2005 durch die beiden japanischen Pharmafirmen Sankyō K.K. (三共株式会社, engl …   Deutsch Wikipedia Daiichi Sankyo — Création 2005 Site web www.daiichisankyo.co.jp …   Wikipédia en Français Daiichi Sankyo Co. — which are pharmaceutical companies based in Japan. Its main offices are located in Chūō, Tokyo. Acquisitions On June 10, 2008, Daiichi Sankyo Co., agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at… …   Wikipedia Daiichi Pharmaceutical — Daiichi Sankyō K.K. (jap. 第一三共株式会社, Daichi Sankyō Kabushiki gaisha, engl. Daiichi Sankyo Co., Ltd.) ist eine gemeinsame japanische Holdinggesellschaft, die am 28. September 2005 durch die beiden japanischen Pharmafirmen Sankyō K.K. (三共株式会社, engl …   Deutsch Wikipedia Daiichi Seiyaku — Daiichi Sankyō K.K. (jap. 第一三共株式会社, Daichi Sankyō Kabushiki gaisha, engl. Daiichi Sankyo Co., Ltd.) ist eine gemeinsame japanische Holdinggesellschaft, die am 28. September 2005 durch die beiden japanischen Pharmafirmen Sankyō K.K. (三共株式会社, engl …   Deutsch Wikipedia Sankyo — Daiichi Sankyō K.K. (jap. 第一三共株式会社, Daichi Sankyō Kabushiki gaisha, engl. Daiichi Sankyo Co., Ltd.) ist eine gemeinsame japanische Holdinggesellschaft, die am 28. September 2005 durch die beiden japanischen Pharmafirmen Sankyō K.K. (三共株式会社, engl …   Deutsch Wikipedia Sankyo — means third one in Japanese. It may refer to:* Daiichi Sankyo Co. * A principle in Aikido referred to as third teaching (which includes certain wristlocks) *Sankyo Flute Company, which produces silver, 5K, 10K, 14K, 18K, and 24K gold flutes *… …   Wikipedia Sankyō — steht für: Sankyō (Aikidō), Haltetechnik der japanischen Selbstverteidigungskunst Aikido Daiichi Sankyō, japanisches Unternehmen Diese Seite ist eine Begriffsklärung zur Unterscheidung mehrerer mit demselben Wort bezeichnete …   Deutsch Wikipedia 18+ © Academic, 2000-2024 Contact us: Technical Support, Advertising Dictionaries export, created on PHP, Joomla, Drupal, WordPress, MODx. Mark and share Search through all dictionaries Translate… Search Internet Share the article and excerpts Direct link … Do a right-click on the link above and select “Copy Link”